Table of Contents Author Guidelines Submit a Manuscript
Evidence-Based Complementary and Alternative Medicine
Volume 2017, Article ID 9651371, 6 pages
https://doi.org/10.1155/2017/9651371
Research Article

Salidroside Modulates Insulin Signaling in a Rat Model of Nonalcoholic Steatohepatitis

1Department of Hepatology, Ningbo No. 2 Hospital, Ningbo, Zhejiang 315010, China
2Medical School of Ningbo University, Ningbo, Zhejiang 315211, China

Correspondence should be addressed to Hongshan Li; moc.621@2891_nahsgnohil

Received 17 November 2016; Revised 10 January 2017; Accepted 11 January 2017; Published 1 February 2017

Academic Editor: Jae Youl Cho

Copyright © 2017 Hongshan Li et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. M. E. Rinella and A. J. Sanyal, “Management of NAFLD: a stage-based approach,” Nature Reviews Gastroenterology and Hepatology, vol. 13, no. 4, pp. 196–205, 2016. View at Publisher · View at Google Scholar · View at Scopus
  2. E. M. Brunt, V. W. Wong, V. Nobili et al., “Nonalcoholic fatty liver disease,” Nature Reviews Disease Primers, vol. 1, Article ID 15080, 2015. View at Publisher · View at Google Scholar
  3. G. Musso, M. Cassader, and R. Gambino, “Non-alcoholic steatohepatitis: emerging molecular targets and therapeutic strategies,” Nature Reviews Drug Discovery, vol. 15, no. 4, pp. 249–274, 2016. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Mintziori and S. A. Polyzos, “Emerging and future therapies for nonalcoholic steatohepatitis in adults,” Expert Opinion on Pharmacotherapy, vol. 17, no. 14, pp. 1937–1946, 2016. View at Publisher · View at Google Scholar
  5. S. A. Polyzos and C. S. Mantzoros, “Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: a systematic review,” Metabolism: Clinical and Experimental, vol. 65, no. 9, pp. 1297–1306, 2016. View at Publisher · View at Google Scholar · View at Scopus
  6. L. Zhang and D. Schuppan, “Traditional Chinese Medicine (TCM) for fibrotic liver disease: hope and hype,” Journal of Hepatology, vol. 61, no. 1, pp. 166–168, 2014. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Wang, L. Luo, L. Yao et al., “Salidroside improves glucose homeostasis in obese mice by repressing inflammation in white adipose tissues and improving leptin sensitivity in hypothalamus,” Scientific Reports, vol. 6, Article ID 25399, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. X.-R. Zhang, X.-J. Fu, D.-S. Zhu et al., “Salidroside-regulated lipid metabolism with down-regulation of miR-370 in type 2 diabetic mice,” European Journal of Pharmacology, vol. 779, pp. 46–52, 2015. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Nabavi, N. Braidy, I. E. Orhan, A. Badiee, M. Daglia, and S. M. Nabavi, “Rhodiola rosea L. and Alzheimer's disease: from farm to pharmacy,” Phytotherapy Research, vol. 30, no. 4, pp. 532–539, 2016. View at Publisher · View at Google Scholar · View at Scopus
  10. Z. R. Yang, H. F. Wang, T. C. Zuo, L. L. Guan, and N. Dai, “Salidroside alleviates oxidative stress in the liver with non- alcoholic steatohepatitis in rats,” BMC Pharmacology & Toxicology, vol. 17, article 16, 2016. View at Publisher · View at Google Scholar
  11. H. Zou, X. Liu, T. Han et al., “Salidroside protects against cadmium-induced hepatotoxicity in rats via GJIC and MAPK pathways,” PLoS ONE, vol. 10, no. 6, Article ID e0129788, 2015. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Tan, W. Lao, L. Xiao et al., “Managing the combination of nonalcoholic fatty liver disease and metabolic syndrome with Chinese herbal extracts in high-fat-diet fed rats,” Evidence-Based Complementary and Alternative Medicine, vol. 2013, Article ID 306738, 10 pages, 2013. View at Publisher · View at Google Scholar · View at Scopus
  13. D. M. Torres, F. J. Jones, J. C. Shaw, C. D. Williams, J. A. Ward, and S. A. Harrison, “Rosiglitazone versus rosiglitazone and metformin versus rosiglitazone and losartan in the treatment of nonalcoholic steatohepatitis in humans: a 12-month randomized, prospective, open- label trial,” Hepatology, vol. 54, no. 5, pp. 1631–1639, 2011. View at Publisher · View at Google Scholar · View at Scopus
  14. K. R. Chi, “The NASH drug dash,” Nature Reviews Drug Discovery, vol. 14, no. 7, pp. 447–448, 2015. View at Publisher · View at Google Scholar · View at Scopus
  15. P.-P. Si, J.-L. Zhen, Y.-L. Cai, W.-J. Wang, and W.-P. Wang, “Salidroside protects against kainic acid-induced status epilepticus via suppressing oxidative stress,” Neuroscience Letters, vol. 618, pp. 19–24, 2016. View at Publisher · View at Google Scholar · View at Scopus
  16. S. Wang, H. He, L. Chen, W. Zhang, X. Zhang, and J. Chen, “Protective effects of salidroside in the MPTP/MPP+-induced model of Parkinson's disease through ROS-NO-related mitochondrion pathway,” Molecular Neurobiology, vol. 51, no. 2, pp. 718–728, 2015. View at Publisher · View at Google Scholar · View at Scopus
  17. Y. Yuan, S.-J. Wu, X. Liu, and L.-L. Zhang, “Antioxidant effect of salidroside and its protective effect against furan-induced hepatocyte damage in mice,” Food and Function, vol. 4, no. 5, pp. 763–769, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. J. R. Krycer, L. J. Sharpe, W. Luu, and A. J. Brown, “The Akt-SREBP nexus: cell signaling meets lipid metabolism,” Trends in Endocrinology and Metabolism, vol. 21, no. 5, pp. 268–276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  19. S. Townsend and P. N. Newsome, “Non-alcoholic fatty liver disease in 2016,” British Medical Bulletin, vol. 119, no. 1, pp. 143–156, 2016. View at Publisher · View at Google Scholar
  20. T. Zheng, X. Yang, D. Wu et al., “Salidroside ameliorates insulin resistance through activation of a mitochondria-associated AMPK/PI3K/Akt/GSK3β pathway,” British Journal of Pharmacology, vol. 172, no. 13, pp. 3284–3301, 2015. View at Publisher · View at Google Scholar · View at Scopus
  21. D. Dattaroy, R. K. Seth, S. Das et al., “Sparstolonin B attenuates early liver inflammation in experimental NASH by modulating TLR4 trafficking in lipid rafts via NADPH oxidase activation,” American Journal of Physiology—Gastrointestinal and Liver Physiology, vol. 310, no. 7, pp. G510–G525, 2016. View at Publisher · View at Google Scholar
  22. Z. Ma, L. Chu, H. Liu et al., “Paeoniflorin alleviates non-alcoholic steatohepatitis in rats: involvement with the ROCK/NF-κB pathway,” International Immunopharmacology, vol. 38, pp. 377–384, 2016. View at Publisher · View at Google Scholar · View at Scopus
  23. Y. Luo, X. Dong, Y. Yu, G. Sun, and X. Sun, “Total aralosides of aralia elata (Miq) seem (TASAES) ameliorate nonalcoholic steatohepatitis by modulating IRE1α-mediated JNK and NF-κB pathways in ApoE–/– mice,” Journal of Ethnopharmacology, vol. 163, pp. 241–250, 2015. View at Publisher · View at Google Scholar · View at Scopus